Clinical question comments:What are the best modalities for accurately staging early oesophageal adenocarcinoma?/Evidence summary and recommendations

Instructions for commenting

• Statements regarding the inclusion/exclusion of issues should be clearly supported by scientific evidence, and specifically outline the relevance of the suggested material to the guidelines.
• If you have identified any gaps or errors in the content please suggest suitable text for inclusion.
• Attach any supporting references or newly published evidence to be considered by the author group for inclusion to your comment.

How to post a public comment

1. Create a user account and/or log in with your details
2. To post a comment, click the blue 'Make a new comment' link below
   
3. Fill in the empty boxes

   Warning: You need to fill out the subject line and box!

4. Attach supporting references and any new papers to go with your comment and to be considered by the author group for inclusion by clicking on "Attach academic evidence".
5. Press 'save page' to post your comment!
   

In order to leave a comment, you must be logged into a Cancer Council Australia account.
Log in to your account Create your account

• [Code↑]
• [History↑]

Sorting order: last modified first newest threads first oldest threads first

Contents

Thread title	Replies	Last modified
AANMS Review	0	16:51, 14 July 2014

AANMS Review

• History
• Summarize

The AANMS has reviewed the above Clinical Practice Guidelines and considers the approach in relation to PET/CT and nuclear medicine in oesophageal adenocarcinoma set out in the Guidelines is consistent with other equivalent guidelines. The Association therefore does not have any further comments or recommendations to add.

• More

• History
• Code
• Link to

Janine Sargeant (talk)‎16:51, 14 July 2014